This research study is evaluating a drug called ixazomib (also known as MLN9708) in combination with dexamethasone and rituximab (the regimen is called IDR) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).
Description: Rate of very good partial response or better in patients treated with IDRMeasure: Very good partial response rate (VGPR) for IDR Time: 76 weeks
Description: Overall response including the rate of complete response (CR), partial response (PR), minimal response (MR), stable disease (SD) and progressive disease (PD)Measure: Overall response rate Time: 2 Years
Description: To evaluate the attainment of response, and depth of response and expression of MYD88 L265P and CXCR4-WHIM mutations in WMMeasure: Response rate by MYD88 L265P and CXCR4-WHIM status Time: 2 Years
Single Group Assignment
There is one SNP
Response rate by MYD88 L265P and CXCR4-WHIM status. --- L265P ---
To evaluate the attainment of response, and depth of response and expression of MYD88 L265P and CXCR4-WHIM mutations in WM. --- L265P ---